Blog
RSS FeedPosted by Michael Wonder on 24 Mar 2020
An update on the 2020 annual meeting in Beijing, China
20 March 2020 - Based on the balance of the evidence before the Board, and with the strong support of our ...
Posted by Michael Wonder on 23 Mar 2020
Hansoh Pharma’s Ameile (almonertinib) receives marketing authorisation in China for second-line treatment for patients with EGFR T790 mutation non-small cell lung cancer
19 March 2020 - Hansoh Pharmaceutical Group announced that the National Medical Products Administration has granted marketing authorisation for Ameile ...
Posted by Michael Wonder on 16 Mar 2020
Chinese official warns against U.S. effort to limit foreign medicine supplies
17 March 2020 - A Chinese official on Monday warned that a push by the White House to reduce U.S. ...
Posted by Michael Wonder on 16 Mar 2020
Reliance on China for medicines an emergency
16 March 2020 - The United States has declared a national emergency as a result of the spread of COVID-19. ...
Posted by Michael Wonder on 12 Mar 2020
Coronavirus spurs U.S. efforts to end China’s chokehold on drugs
11 March 2020 - The Trump administration says the U.S. is too dependent on China for vital drugs. But it’s unclear ...
Posted by Michael Wonder on 10 Mar 2020
Global companies expand the reach of their cancer drugs in China
10 March 2020 - While much of the world is understandably focused on the new coronavirus’s emergence in China, three ...
Posted by Michael Wonder on 02 Mar 2020
Erbitux approved for first-line use in China in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
2 March 2020 - Approval is for Erbitux in combination with platinum-based therapy with 5-fluorouracil for the first-line treatment of R/M ...
Posted by Michael Wonder on 15 Feb 2020
China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
14 February 2020 - This marks the first approval for a Tecentriq-based therapy in China, less than a year after the ...
Posted by Michael Wonder on 30 Jan 2020
NRDL list could lead to increased access to innovative drugs in China
27 January 2020 - China has started to regularly update its National Reimbursement Drug List which could lead to new opportunities ...
Posted by Michael Wonder on 22 Jan 2020
Roche wins approval for cancer drug Kadcyla in fast-growing China market
23 January 2020 - Roche said on Wednesday China had approved the import of its Kadcyla drug for breast cancer, another ...
Posted by Michael Wonder on 19 Jan 2020
China drives down drug prices with bulk buy bidding
18 January 2020 - Pharma giants that used to profit from off-patent drugs forced to compete with local generic makers. ...
Posted by Michael Wonder on 07 Jan 2020
Lokelma approved in China for the treatment of adult patients with hyperkalaemia
6 January 2020 - Patients in China will benefit from Lokelma’s rapid reduction of potassium in the blood and the ...
Posted by Michael Wonder on 05 Jan 2020
China National Medical Products Administration approves BeiGene’s tislelizumab for patients with classical Hodgkin’s lymphoma who have received at least two prior therapies
27 December 2019 - Second BeiGene discovered drug to receive regulatory approval, first in China. ...
Posted by Michael Wonder on 24 Dec 2019
AstraZeneca’s triple-combination therapy approved in China for patients with COPD
23 December 2019 - First fixed-dose triple-combination therapy in a pressurised metered-dose inhaler device in China. ...
Posted by Michael Wonder on 16 Dec 2019
China’s cancer patients hit by new law on experimental drug treatments not approved by government
11 December 2019 - The law came into effect on December 1 and forbids pharmaceutical firms giving patients drugs from unapproved ...